1. A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies
   Katharine A. Collier et al, 2021, Cancer Chemotherapy and Pharmacology CrossRef
2. Achiral Derivatives of Hydroxamate AR-42 Potently Inhibit Class I HDAC Enzymes and Cancer Cell Proliferation
   Jiahui Tng et al, 2020, Journal of Medicinal Chemistry CrossRef
3. A quantitative structural analysis of AR-42 derivatives as HDAC1 inhibitors for the identification of promising structural contributors
   R. Kundu et al, 2022, SAR and QSAR in Environmental Research CrossRef